The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer

[1]  A. Skytte,et al.  Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer , 2020, Acta oncologica.

[2]  D. Evans,et al.  Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect , 2018, Breast Cancer Research and Treatment.

[3]  H. Kuerer,et al.  Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer , 2018, Cancer medicine.

[4]  L. Lostumbo,et al.  Risk-reducing mastectomy for the prevention of primary breast cancer. , 2018, The Cochrane database of systematic reviews.

[5]  David Evans,et al.  Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study , 2018, The Lancet. Oncology.

[6]  J. Simard,et al.  Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"? , 2017, American journal of preventive medicine.

[7]  M. Morrow,et al.  Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy? , 2017, Annals of Surgical Oncology.

[8]  Sung-Won Kim,et al.  Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer , 2017, Journal of breast cancer.

[9]  W. Barry,et al.  Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. , 2017, Annals of surgery.

[10]  A. Jena,et al.  Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie’s New York Times editorial , 2016, British Medical Journal.

[11]  Susan M. Astley,et al.  Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study , 2016 .

[12]  I. Bedrosian,et al.  Survey of the Deficits in Surgeons' Knowledge of Contralateral Prophylactic Mastectomy. , 2016, JAMA surgery.

[13]  D. Evans,et al.  Attitudes to contralateral risk reducing mastectomy among breast and plastic surgeons in England. , 2016, Annals of the Royal College of Surgeons of England.

[14]  A. Howell,et al.  Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women , 2015, Breast Cancer Research.

[15]  D. Evans,et al.  The Manchester guidelines for contralateral risk-reducing mastectomy , 2015, World Journal of Surgical Oncology.

[16]  A. Howell,et al.  Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis , 2015, Familial Cancer.

[17]  L. Esserman,et al.  Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer , 2015, Annals of Surgical Oncology.

[18]  D. Evans,et al.  20. Breast surgeons' attitudes towards bilateral risk reducing mastectomy – A comparison between the UK, the US, France and Germany , 2015 .

[19]  D. Evans,et al.  Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies , 2015, International journal of surgical oncology.

[20]  S. Evans,et al.  Growing Use of Mastectomy for Ductal Carcinoma-In Situ of the Breast Among Young Women in the United States , 2015, Annals of Surgical Oncology.

[21]  A. Howell,et al.  The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services , 2014, Breast Cancer Research.

[22]  R. Tollenaar,et al.  Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis , 2014, International journal of cancer.

[23]  A. Howell,et al.  Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme , 2014, Familial Cancer.

[24]  N. Kressin,et al.  The effect of Massachusetts health reform on 30 day hospital readmissions: retrospective analysis of hospital episode statistics , 2014, BMJ : British Medical Journal.

[25]  W. Foulkes,et al.  Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis , 2014, BMJ : British Medical Journal.

[26]  D. Cromwell,et al.  Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics , 2013, BMJ Open.

[27]  D. Evans,et al.  Familial breast cancer: summary of updated NICE guidance , 2013, BMJ.

[28]  I. Buchan,et al.  Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer , 2013, Breast Cancer Research and Treatment.

[29]  M. Golatta,et al.  The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study , 2012, Breast Cancer Research.

[30]  U. Güth,et al.  Increasing rates of contralateral prophylactic mastectomy - a trend made in USA? , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[31]  P. Rosenberg,et al.  Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Tuttle,et al.  Patient and Surgeon Characteristics Associated with Increased Use of Contralateral Prophylactic Mastectomy in Patients with Breast Cancer , 2009, Annals of Surgical Oncology.

[33]  E. Beckjord,et al.  Diagnostic Breast Magnetic Resonance Imaging and Contralateral Prophylactic Mastectomy , 2009, Annals of Surgical Oncology.

[34]  Jan Lubinski,et al.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers , 2008, International journal of cancer.

[35]  P. Møller,et al.  Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  T. Tuttle,et al.  Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A Howell,et al.  Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme , 2003, Journal of medical genetics.

[38]  A. Howell,et al.  A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[39]  J. Goodwin,et al.  Effect of Nancy Reagan's mastectomy on choice of surgery for breast cancer by US women. , 1998, JAMA.

[40]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[41]  A. Giuliano,et al.  Guidelines for Guidelines: An Assessment of the American Society of Breast Surgeons Contralateral Prophylactic Mastectomy Consensus Statement , 2016, Annals of Surgical Oncology.

[42]  M. Dew,et al.  A Prospective Analysis , 2015 .

[43]  M. F. Parry,et al.  A Retrospective Analysis , 1990 .